XBiotech (NASDAQ:XBIT) Earns Daily Media Sentiment Score of 0.05

News articles about XBiotech (NASDAQ:XBIT) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. XBiotech earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.4801347246835 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of XBiotech (NASDAQ:XBIT) traded down $0.10 on Wednesday, hitting $4.37. The stock had a trading volume of 105,700 shares, compared to its average volume of 213,728. XBiotech has a 52 week low of $2.77 and a 52 week high of $20.18.

COPYRIGHT VIOLATION NOTICE: “XBiotech (NASDAQ:XBIT) Earns Daily Media Sentiment Score of 0.05” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/13/xbiotech-xbit-receives-news-impact-score-of-0-05.html.

About XBiotech

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Insider Buying and Selling by Quarter for XBiotech (NASDAQ:XBIT)

Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply